Harrow, Inc. Restricted Cash and Investments, Current
Harrow, Inc. (HROW) had Restricted Cash and Investments, Current of $50.03 thousand as of 2013-06-30, per its 10-Q filed 2013-08-14.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Restricted Cash and Investments, Current
us-gaap:RestrictedCashAndInvestmentsCurrent · last filed 2013-08-14
- 2013-06-30: Restricted Cash and Investments, Current $50.03K.
- 2013-03-31: Restricted Cash and Investments, Current $50.00K.
- 2012-12-31: Restricted Cash and Investments, Current $0.00.
| Period end | Restricted Cash and Investments, Current |
|---|---|
| 2013-06-30 | $50.03K 10-Q · filed 2013-08-14 |
| 2013-03-31 | $50.00K 10-Q · filed 2013-05-08 |
| 2012-12-31 | $0.00 10-Q · filed 2013-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |